Actively Recruiting
Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought
Led by Johns Hopkins University · Updated on 2026-03-02
30
Participants Needed
1
Research Sites
243 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research study will use computerized tasks, electroencephalography (EEG), and magnetic resonance imaging (MRI) to look at how the drug psilocybin, a naturally occurring compound contained in hundreds of species of psychoactive mushrooms, changes thoughts and brain activity.
CONDITIONS
Official Title
Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 to 75 years
- Provided written informed consent
- Have at least a high-school education or equivalent and are fluent in English
- Healthy and psychologically stable based on medical and psychiatric screening including interview, questionnaire, physical exam, ECG, and lab tests
- Agree to consume usual amount of caffeine on drug session mornings or abstain if not a regular caffeine consumer
- Agree to avoid psychoactive drugs, alcohol, and nicotine for 24 hours before drug administration, except caffeine
- Agree not to take any "as-needed" medications on drug session mornings
- Agree to avoid sildenafil, tadalafil, or similar medications within 72 hours of drug administration
- Agree to refrain from nonprescription, nutritional, or herbal supplements for one week before each drug session unless approved
- Have used a psychedelic drug at least five times in their lifetime
- Proof of COVID-19 vaccination
You will not qualify if you...
- Women who are pregnant, nursing, or of child-bearing potential and sexually active without effective birth control
- Cardiovascular diseases including coronary artery disease, stroke, angina, uncontrolled hypertension, significant ECG abnormalities, artificial heart valve, or recent heart attack
- Epilepsy or history of seizures
- Insulin-dependent diabetes or history of hypoglycemia if on oral hypoglycemics
- Regular daily use of psychoactive prescription medications
- Regular daily use of medications affecting serotonin, including MAOIs, without sufficient washout
- Body weight more than 20% outside ideal range
- Current or past schizophrenia spectrum or other psychotic disorders
- Moderate or severe alcohol or drug use disorder in past five years
- First or second-degree relative with bipolar I, schizophrenia spectrum, or psychotic disorders
- Psychiatric conditions incompatible with safe psilocybin exposure
- History of migraine, tension, or recurring headaches
- Significant head trauma with loss of consciousness over 2 minutes
- Contraindications for MRI, including claustrophobia or incompatible implants
- Left-handedness assessed by Edinburgh Handedness Inventory
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Johns Hopkins Center for Psychedelic and Consciousness Research
Baltimore, Maryland, United States, 21224
Actively Recruiting
Research Team
G
Gabi Lofland
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here